Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.


Surotomycin (CB-183,315), a cyclic lipopeptide, is in phase 3 clinical development for the treatment of Clostridium difficile infection. We report here the further characterization of the in vitro mode of action of surotomycin, including its activity against growing and nongrowing C. difficile. This was assessed through time-kill kinetics, allowing a… (More)
DOI: 10.1128/AAC.01087-15


  • Presentations referencing similar topics